Topoisomerase 2 alpha and the case for individualized breast cancer therapy

Annals of Surgical Oncology

Volumn 17, Issue 5, 2010, Pages 1392-1397

  Glynn, Ronan W ^a   Miller, Nicola ^a   Whelan, Maria C ^a   Kerin, Michael J ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING) A; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; TAMOXIFEN; THIOTEPA;

AMPLICON; BREAST CANCER; CHROMOSOME 17; CORRELATION ANALYSIS; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; IMMUNOHISTOCHEMISTRY; PREDICTIVE VALIDITY; REVIEW; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE;

ANTHRACYCLINES; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; GENE AMPLIFICATION; HUMANS; INDIVIDUALIZED MEDICINE; PROGNOSIS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 77952094228     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-009-0855-0     Document Type: Review

References (28)

1. T Sorlie CM Perou R Tibshirani, et al. 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proceedings of the National Academy of Sciences of the United States of America 98 19 10869 10874 10.1073/pnas.191367098 1:CAS:528:DC%2BD3MXntVGmsbo%3D 11553815 (Pubitemid 32878711)
2. R Clarke MC Liu KB Bouker, et al. 2003 Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling Oncogene 22 7316 7339 10.1038/sj.onc.1206937 1:CAS:528:DC%2BD3sXotlajurw%3D 14576841 (Pubitemid 37492898)
3. M Jansen JA Foekens IL van Staveren, et al. 2005 Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling J Clin Oncol 23 732 740 10.1200/JCO.2005.05.145 1:CAS:528:DC%2BD2MXitVKitr4%3D 15681518 (Pubitemid 46224172)
4. A Gennari P Pronzato 2008 New understanding of the role of anthracyclines in early-stage breast cancer: Patient selection considerations Clin Breast Cancer 8 Suppl 4 S179 S183 10.3816/CBC.2008.s.015 1:CAS:528:DC%2BD1MXitVyqur8%3D 19158039
5. AD Thor DA Berry DR Budman, et al. 1998 erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer J Natl Cancer Inst 90 1346 1360 10.1093/jnci/90.18.1346 1:CAS:528:DyaK1cXmtlelur4%3D 9747866
6. SM Paik J Bryant CH Park, et al. 1998 erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer J Natl Cancer Inst 90 1361 1370 10.1093/jnci/90.18.1361 1:CAS:528:DyaK1cXmtlelurw%3D 9747867 (Pubitemid 28439960)
7. KI Pritchard LE Shepherd FP O'Malley, et al. 2006 HER2 and responsiveness of breast cancer to adjuvant chemotherapy N Engl J Med 354 2103 2111 10.1056/NEJMoa054504 1:CAS:528:DC%2BD28XkslCku7s%3D 16707747 (Pubitemid 43736610)
8. O Abe R Abe K Enomoto, et al. 1998 Polychemotherapy for early breast cancer: An overview of the randomised trials Lancet 352 930 942 10.1016/S0140-6736(98)03301-7 (Pubitemid 28427277)
9. M Tanner J Isola T Wiklund, et al. 2006 Topoisomerase II alpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401 J Clin Oncol 24 2428 2436 10.1200/JCO.2005.02.9264 1:CAS:528:DC%2BD28XmtVOmsLc%3D 16682728 (Pubitemid 46630618)
10. A Gennari MP Sormani P Pronzato, et al. 2008 HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: A pooled analysis of randomized trials J Natl Cancer Inst 100 14 20 1:CAS:528:DC%2BD1cXit1Cku7o%3D 18159072 (Pubitemid 351767337)
11. TA Jarvinen M Tanner M Barlund A Borg J Isola 1999 Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer Genes Chromosomes Cancer 26 142 150 10.1002/(SICI)1098-2264(199910)26:2<142::AID- GCC6>3.0.CO;2-B 1:CAS:528:DyaK1MXmt1WhsLc%3D 10469452 (Pubitemid 29416439)
12. TA Jarvinen M Tanner V Rantanen, et al. 2000 Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer Am J Pathol 156 839 847 1:CAS:528:DC%2BD3cXitVerurc%3D 10702400 (Pubitemid 30626942)
13. RE Mueller RK Parkes I Andrulis FP O'Malley 2004 Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples Genes Chromosomes Cancer 39 288 297 10.1002/gcc.20008 1:CAS:528:DC%2BD2cXivFKjsbw%3D 14978790 (Pubitemid 38326310)
14. R Bhargava P Lal B Chen 2005 HER-2/neu and topoisomerase IIa gene amplification and protein expression in invasive breast carcinomas: Chromogenic in situ hybridization and immunohistochemical analyses Am J Clin Pathol 123 889 895 10.1309/PCFK8YTQPYWD534F 1:CAS:528:DC%2BD2MXlsFSks7w%3D 15899781 (Pubitemid 40740688)
15. JS Coon E Marcus S Gupta-Burt, et al. 2002 Amplification and overexpression of topoisomerase II alpha predict response to anthracycline-based therapy in locally advanced breast cancer Clin Cancer Res 8 1061 1067 1:CAS:528:DC%2BD38XjsF2ltr8%3D 11948114 (Pubitemid 35177356)
16. E Arriola SM Rodriguez-Pinilla MBK Lambros, et al. 2007 Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer Breast Cancer Res Treat 106 181 189 10.1007/s10549-006-9492-5 1:CAS:528:DC%2BD2sXht1CgtL7M 17260090 (Pubitemid 350045015)
17. AR Beser S Tuzlali D Guzey, et al. 2007 HER-2, TOP2A and chromosome 17 alterations in breast cancer Pathol Oncol Res 13 180 185 10.1007/BF02893497 17922046 (Pubitemid 350221219)
18. AM Bofin B Ytterhus BM Hagmar 2003 TOP2A and HER-2 gene amplification in fine needle aspirates from breast carcinomas Cytopathology 14 314 319 10.1046/j.0956-5507.2003.00088.x 1:STN:280:DC%2BD3sngtVahsA%3D%3D 14632728 (Pubitemid 37521861)
19. Knoop AS, Knudsen H, Balslev E, et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol. 2005;23:7483-90. [Erratum appears in J Clin Oncol. 2006;24:1015]. (Pubitemid 46291811)
20. L Orlando B Del Curto S Gandini, et al. 2008 Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer Breast 17 506 511 10.1016/j.breast.2008.03.007 18456496
21. DS Murphy P McHardy J Coutts, et al. 1995 Interphase cytogenetic analysis of ERBB2 and TOPOII-alpha coamplification in invasive breast-cancer and polysomy of chromosome-17 in ductal carcinoma in-situ Int J Cancer 64 18 26 10.1002/ijc.2910640106 1:STN:280:DyaK2MzpsVGgsQ%3D%3D 7665243
22. DG Hicks BJ Yoder J Pettay, et al. 2005 The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: A fluorescence in situ hybridization study Hum Pathol 36 348 356 10.1016/j.humpath.2005.01.016 1:CAS:528:DC%2BD2MXjsFGqs7Y%3D 15891995 (Pubitemid 40591804)
23. FP O'Malley S Chia D Tu, et al. 2009 Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy J Natl Cancer Inst 101 644 650 10.1093/jnci/djp067 19401546
24. JMS Bartlett A Munro DA Cameron, et al. 2008 Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial J Clin Oncol 26 5027 5035 10.1200/JCO.2007.14.6597 1:CAS:528:DC%2BD1cXhsVGhsrrE 18768436
25. Usha L, Tabesh B, Morrison LE, et al. Topoisomerase II alpha gene copy loss has adverse prognostic significance in ERBB2-amplified breast cancer: A retrospective study of paraffin-embedded tumor specimens and medical charts. J Haemat Oncol. 2008;1.
26. S Withoff S de Jong EGE de Vries NH Mulder 1996 Human DNA topoisomerase 2. Biochemistry and role in chemotherapy resistance (review) Anticancer Res 16 1867 1880 1:CAS:528:DyaK28XltFyks7g%3D 8712715 (Pubitemid 26270698)
27. K Park J Kim S Lim S Han 2003 Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy Eur J Cancer 39 631 634 10.1016/S0959-8049(02)00745-1 1:CAS:528:DC%2BD3sXhvFGkurk%3D 12628842 (Pubitemid 36287375)
28. J Bergh T Wiklund B Erikstein, et al. 2000 Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: A randomised trial. Scandinavian Breast Group 9401 study Lancet 356 1384 1391 10.1016/S0140-6736(00)02841-5 1:CAS:528:DC%2BD3cXot1WqtL4%3D 11052580 (Pubitemid 32047972)